The United Kingdom and the United States have secured a major trade agreement that will guarantee zero duties on UK drug products going into the American market.
The Terms of the Accord
As part of the deal, the UK has committed to raise expenditure on pharmaceuticals through the NHS. This commitment secures that import taxes on these crucial products will be held at zero for a period of the next three years.
This agreement comes after recent statements to significantly raise tariffs on branded drug imports, with increases mentioned as high as one hundred percent.
"This deal between the UK strengthens the global environment for cutting-edge drugs and brings much-needed fairness to transatlantic drug exports," a statement said.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the US, which is easily the primary destination for leading UK drugmakers.
Statistics indicate that in the 12 months leading up to September, the UK shipped drugs valued at £11.1bn to the US. This value made up 17.4% of British export trade in that span.
"This guarantee safeguards employment, increases capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a minister remarked.
Specific NHS Changes
The pact involves several specific commitments from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to double total public funding on drugs from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates topped 20%.
Broader Context
The pact follows a ongoing tension between the sector and the ministers over drug pricing and NHS adoption.
These tensions were heightened by claims that US consumers were charged a premium for the equivalent treatments than people in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
